Welcome to STN International! Enter x:x

LOGINID:ssspta1600rxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS	9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	10	SEP 22	DIPPR file reloaded
NEWS	11	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS	12	SEP 29	DISSABS now available on STN
NEWS	13	OCT 10	PCTFULL: Two new display fields added
NEWS	14	OCT 21	BIOSIS file reloaded and enhanced
NEWS	15	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced

NEWS EXPRESS	OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:52:03 ON 04 NOV 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:52:11 ON 04 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 NOV 2003 HIGHEST RN 612478-18-9
DICTIONARY FILE UPDATES: 3 NOV 2003 HIGHEST RN 612478-18-9

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10089433.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 07:52:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 190 TO ITERATE

100.0% PROCESSED 190 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2973 TO 4627
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:52:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3403 TO ITERATE

100.0% PROCESSED 3403 ITERATIONS 15 ANSWERS

SEARCH TIME: 00.00.01

L3 15 SEA SSS FUL L1

=> d scan

L3 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-(2-(1-methylethyl)phenyl)- (9CI)
MF C15 H16 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):14

L3 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(3-furanylthio)-N-phenyl- (9CI)
MF C12 H10 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(3-furanylthio)-N-[2-(1-methylethyl)phenyl] (9CI)
MF C15 H16 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-(4-methylphenyl)- (9CI)
MF C13 H12 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-(3-methylphenyl)- (9CI)
MF C13 H12 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(4-furanylthio)-N-(4-methylphenyl)- (9CI)
MF C13 H12 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(4-furanylthio)-N-(3-methylphenyl)- (9CI)
MF C13 H12 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-(2-methylphenyl)- (9CI)
MF C13 H12 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, N-(4-fluorophenyl)-5-(2-furanylthio)- (9CI)
MF C12 H9 F N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-(2-methylphenyl)- (9CI)
MF C13 H12 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, N-(4-fluorophenyl)-5-(2-furanylthio)- (9CI)
MF C12 H9 F N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-(2-methoxyphenyl)- (9CI)
MF C13 H12 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 2-Furancarboxylic acid, 3-[[(5-amino-1H-1,2,4-triazol-3-yl)thio]-2-[[(5-amino-1H-1,2,4-triazol-3-yl)thio]methyl]-2,5-dihydro-4-hydroxy-5-oxo-, ethyl ester (9CI)
MF C12 H14 N8 O5 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(3-furanylthio)-N-(2-methoxyphenyl)- (9CI)
MF C13 H12 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 15 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-phenyl- (9CI)
MF C12 H10 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   148.55     148.76

FILE 'CAPLUS' ENTERED AT 07:53:18 ON 04 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 4 Nov 2003  VOL 139 ISS 19
FILE LAST UPDATED: 3 Nov 2003  (20031103/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3
L4            2 L3

=> d ibib abs hitstr 1-2
```

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:610432 CAPLUS
DOCUMENT NUMBER: 139:179965
TITLE: Preparation of furanones as cyt protectants for neuroinflammation and neurodegenerative disorders
INVENTOR(S): Wang, Ping; Zhang, Wei; Song, Jianjun; Del Balzo, Uwhetta; Brown, Lesley; Walkinshaw, Gail
PATENT ASSIGNEE(S): Galileo Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064403	A1	20030807	WO 2003-US2766	20030130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SK, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003176361	A1	20030918	US 2003-354474	20030128

PRIORITY APPLN. INFO.: US 2002-3579398P P 20020131
OTHER SOURCE(S): MARPAT 139:179965
GI



I



II

AB Title compds. I [wherein R1 = CO2R', CONR'R'', CH2CR'''', CN, (un)substituted heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl; R2, R3 = independently (un)substituted alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, nucleoside, amino acid, di-, tri- or tetra-peptide; R4 = H, alkyl, alkylcarbonyl, (poly)alkoxyalkylene, dialkoxyphosphinyloxy; X = alkylene, NR', S, SO, SO2; or XR2 = P(OR')2; Y = NR', S, SO, SO2; or YR3 = P(OR')2; or XR2YR3 = (un)substituted aliph. or arom. ring; R' = H, alkenyl, (un)substituted alkyl, cycloalkyl, phosphoryl, aryl; R'' = H, alkenyl, (un)substituted alkyl, aryl; or R'R'' = atoms that form (un)substituted 5-7 membered aryl, heteroaryl ring; R''' = H, alkenyl, (un)substituted alkyl, acyl, cycloalkyl, phosphoryl, aryl; with the proviso that the compd. is not 4-hydroxy-3-methanylsulfonyl-2 methanylsulfonylmethyl-5-exo-2,5-dihydr.furan-2 carboxylic acid Et ester; and further with the proviso that when X = alkylene, R2 = (un)substituted alkyl; and their single tautomers, single stereoisomers, mixts. of tautomers and/or stereoisomers, and pharmaceutically acceptable salts] were prepd. as cytoprotectants for neuroinflammation and neurodegenerative disorders. For example, II was prepd. by reaction of 2-mercaptobenzimidazole with Et bromopyruvate in ethanol/acetone and aldol condensation of the two tautomeric forms of the pyruvate intermediate. Selected invention compds. showed significant redn. in edema in assays assessing mouse ear inflammatory response to topical arachidonic acid (IC50 to 70%, $p < 0.05$). Results from neuronal cell stress assay, myocyte calcium-contractility assay, and rat middle cerebral artery occlusion model were disclosed for selected invention compds. Thus, I and their pharmaceutical formulations are useful in the treatment of stroke, cerebral ischemia, myocardial infarction, myocardial ischemia, chronic heart failure, inflammation and other oxidative stress-related conditions, and Alzheimer's disease and senile dementia (no data).

IT **577952-50-2P**, 3-[[5-Amino-2H-[1,2,4]triazol-3-yl)sulfanyl)-2-[[(5-amino-2H-[1,2,4]triazol-3-yl)sulfanyl)methyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-2-carboxylic acid ethyl ester RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cytoprotective agents; prepn. of furanone cytoprotectants via aldol condensation for treatment of neuroinflammation and neurodegenerative disorders)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

RN 577952-50-2 CAPLUS
CN 2-Furancarboxylic acid, 3-[[(5-amino-1H-1,2,4-triazol-3-yl)thio]-2-[[(5-amino-1H-1,2,4-triazol-3-yl)thio]methyl]-2,5-dihydro-4-hydroxy-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:266251 CAPLUS
DOCUMENT NUMBER: 134:295827
TITLE: 3 Anilino 5 benzylthio-1,2,4-triazoles and analogous compounds and methods of use as inhibitors of type 2 methionine aminopeptidase (MetAP2)
INVENTOR(S): Marion, Joseph P., Jr.; Thompson, Scott K.; Vebel, Daniel Frank
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024796	A1	20010412	WO 2000-US26951	20000929
W: AE, AL, AM, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KR, KC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1223932	A1	20020724	EP 2000-970527	20000929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003510359	T2	20030318	JP 2001-527795	20000929

PRIORITY APPLN. INFO.: US 1999-157286P P 19991001
WO 2000-US26951 W 20000929
OTHER SOURCE(S): MARPAT 134:295827
GI



I



II

AB The compds. of the invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase (MetAP2), and are useful in treating conditions mediated by angiogenesis, such as cancer, hemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization, and obesity. In particular, the method of inhibiting MetAP2 with triazoles I and their

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
pharmaceutically acceptable salts and solvates is claimed [wherein: X = S or O; R1 = (un)substituted C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, (un)substituted aralkyl, (un)substituted heterocyclylalkyl, or cycloalkylalkyl; R2 = (un)substituted C2-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, (un)substituted aralkyl, (un)substituted heterocyclylalkyl, cycloalkylalkyl; R3 = H, (un)substituted C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, (un)substituted aralkyl, (un)substituted heterocyclylalkyl, cycloalkylalkyl, alkyl-C(O)-X'AR, alkyl-S(O)X'AR, alkyl-X'AR; X' = O, S, C or N; A, B = H, (un)substituted C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, (un)substituted aralkyl, (un)substituted heterocyclylalkyl, cycloalkylalkyl; A and/or B may be absent]. A total of 312 synthetic examples are given. For instance, treatment of thiourea with NaOH and then PhCH2OCOCl gave 1-phenyl 2,4-dithiobiuret, i.e., PhNHC(:S)NHC(:S)NH2, which reacted with NEt3 and Et2 in DMF to give 2-ethyl-1-phenyl 2-isodithiobiuret, i.e., PhNHC(SEt):NC(:S)NH2. Cyclocondensation of the latter with anhyd. hydrazine gave 3-anilino-5-mercapto-1,2,4-triazole, which reacted with K2CO3 and benzyl bromide in DMF to give the invention compd. 3-anilino-5-benzylthio-1,2,4-triazole. Using analogous substituted starting materials, more highly substituted invention compds. such as II were prepd. The compds. have IC50 values of 0.0001-100 .mu.M against MetAP2.

IT **334538-78-2P**, 3-Anilino-5-(furan-2-ylthio)-1,2,4-triazole
334538-87-3P, 3-Anilino-5-(furan-3-ylthio)-1,2,4-triazole
334538-99-7P, 3-(4-Methylanilino)-5-(furan-2-ylthio)-1,2,4-triazole **334539-08-1P**, 3-(4-Methylanilino)-5-(furan-3-ylthio)-1,2,4-triazole **334539-21-8P**, 3-(2-Methylanilino)-5-(furan-2-ylthio)-1,2,4-triazole **334539-30-9P**, 3-(2-Methylanilino)-5-(furan-3-ylthio)-1,2,4-triazole **334540-40-8P**, 3-(2-Methoxyanilino)-5-(furan-2-ylthio)-1,2,4-triazole **334540-48-6P**, 3-(2-Methoxyanilino)-5-(furan-3-ylthio)-1,2,4-triazole **334540-63-5P**, 3-(2-Isopropylanilino)-5-(furan-2-ylthio)-1,2,4-triazole **334540-71-5P**, 3-(2-Isopropylanilino)-5-(furan-3-ylthio)-1,2,4-triazole **334540-86-2P**, 3-(3-Methylanilino)-5-(furan-2-ylthio)-1,2,4-triazole **334540-95-3P**, 3-(3-Methylanilino)-5-(furan-3-ylthio)-1,2,4-triazole **334541-50-3P**, 3-(4-Fluoroanilino)-5-(furan-2-ylthio)-1,2,4-triazole **334541-61-6P**, 3-(4-Fluoroanilino)-5-(furan-3-ylthio)-1,2,4-triazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of anilino(benzylthio)triazole derivs. as MetAP2 inhibitors)

RN 334538-78-2 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-phenyl- (9CI) (CA INDEX NAME)



RN 334538-87-3 CAPLUS

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN 1H-1,2,4-Triazol-3-amine, 5-(3-furanylthio)-N-phenyl- (9CI) (CA INDEX NAME)



RN 334538-99-7 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 334539-08-1 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(3-furanylthio)-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 334539-21-8 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 334539-30-9 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(3-furanylthio)-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 334540-40-8 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 334540-48-6 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(3-furanylthio)-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 334540-63-5 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 334540-71-5 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(3-furanylthio)-N-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 334540-86-2 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(2-furanylthio)-N-(3-methylphenyl) (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 334540-95-3 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, 5-(3-furanylthio)-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 334541-50-3 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, N-(4-fluorophenyl)-5-(2-furanylthio) (9CI) (CA INDEX NAME)



RN 334541-61-6 CAPLUS
CN 1H-1,2,4-Triazol-3-amine, N-(4-fluorophenyl)-5-(3-furanylthio) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   10.32     159.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -1.30      -1.30

STN INTERNATIONAL LOGOFF AT 07:55:02 ON 04 NOV 2003
```